OMCL Stock Omnicell, Inc.
US · NasdaqGSLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Automation demand and strong analyst consensus support meaningful rerating potential.
Future value: $57.86 (+53.26%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Strong Buy consensus and multiple Buy ratings with $56 target.
- ▸Above 50-day MA (+9.22%)
- ▸~53% upside to price target
Is OMCL a buy right now?
Trend: OMCL is trading above the 50-day average (+9.23%), RSI 57 — neutral momentum, with a 3-month return of -9.01%.
Valuation & quality: Omnicell, Inc. trades on a trailing P/E of 44.0, forward P/E 18.0, PEG 15.40, price-to-book 1.31; fundamentals show net margin 3.1%, return on equity 3.1%, revenue growth 7.5% year on year.
Analyst consensus: 7 analysts have a mean 12-month price target of $57.86 (+56.5% vs the last close; range $45.00 – $70.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 4) — Automation demand and strong analyst consensus support meaningful rerating potential.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -18.80% | +24.10% | +6.60% | -5.90% | -14.80% | -0.60% | -3.20% | +10.90% |
Fundamentals
Analyst price target
Technical signals
About Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
Sector: Healthcare · Industry: Health Information Services · United States · 3,485 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.